When breast imaging comes to mind, mammography is the undisputed current modality of choice. Used as the primary screening tool for breast cancer, other breast imaging (BI) modalities, such as magnetic resonance imaging (MRI) and ultrasound, form a comparatively smaller part of the market. For this reason, it is mammography which has typically driven the majority of BI’s market growth.


This case study reports on the outcomes achieved with GE Healthcare OEC Elite CFD mobile C-arms with CMOS flat panel detectors (CFD) in a variety of clinical settings by an interventional cardiology endovascular surgeon and an interventionalist specializing in pain management. Those results include good image quality at lower dose and improved workflow efficiency.


At the American Society for Radiation Oncology’s (ASTRO) 2019 annual meeting, the society’s leadership introduced a new format for its Presidential Symposium.



For the last several years, artificial intelligence (AI) has represented the newest, most rapidly expanding frontier of radiology technology. Expo floors at all the major professional society meetings are full of vendors showcasing AI tools they have developed or integrated into their products, billed as efficiency and time-savings aids to help ease the workload of radiologists who are increasingly bogged down by vast amounts of data.


When it comes to the use of mammography skin markers in digital breast tomosynthesis (DBT) or 3-D mammography, care has to be taken to use the correct markers. With many sites performing both a full field digital mammogram (2-D) and a 3-D exam at one time, many sites are using the markers that they have had for 2-D exams. What many radiologists did not realize is that the older markers are not ideal for the 3-D images.

Windsong Radiology Group is a New York-based radiology practice with five locations. Recently, Windsong participated in a controlled commercial release (CCR) of the MEDRAD Stellant FLEX Injection System, the newest MEDRAD CT Injection System.


Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a cause of contrast-induced nephropathy (CIN). This has raised concern in recent years, especially in renally compromised patients, and imagers are looking for ways to reduce the contrast media dose levels they use.



The advancement of medical technology offers a plethora of options for healthcare professionals and patients alike. New technologies and clinical trials are solving the way we treat diseases and interface with patients. Recent breakthroughs in three-dimensional printing (3-D) may have hit upon a solution for organ failure.1


As the largest provider of inpatient and outpatient services in New Jersey, Hackensack Meridian Health Hackensack University Medical Center caters to a diverse patient population.

The 775-bed, nonprofit teaching and research hospital tends to everyone from the elderly to newborn infants. But as any clinician will tell you, patient needs vary not only according to their disease states, but according to their age or life stage, as well.

Subscribe Now